Severe and long‐lasting disruption of T‐cell receptor diversity in human myeloma after high‐dose chemotherapy and autologous peripheral blood progenitor cell infusion

Abstract excerpt

Vaccine-based strategies are currently under investigation as a means of inducing tumour-specific immune responses and improving the clinical outcome of multiple myeloma (MM) patients in remission after high-dose chemotherapy and peripheral blood progenitor cell (PBPC) infusion. The immune competence of these patients was investigated by determining the overall diversity of the T-cell receptor (TCR) repertoire in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immunotherapy and Immune Responses
• Share to Multiple Myeloma Research and Treatments
• Share to T-cell and B-cell Immunology